In the article by M. Esteller et al., entitled “Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients,” which appeared in the January 1, 1999 issue of Cancer Research (pp. 67–70), the primer sequences of the MGMT gene were incorrectly listed in the “Materials and Methods” section as 5′-ATG GTA TGG ATT TTA GTG TTG GTT-3′ (sense) and 5′-ACT ATA CCT AAA CTC AAC AAA CAC CA-3′ for the unmethylated reaction and 5′-GTA TGG ATT TTA GCG TCG GTC-3′ (sense) and 5′-TAA ACT CGA CGA ACG CCG-3′ (antisense) for the methylated reaction. The correct primer sequences of the MGMT gene are 5′-TTT GTG TTT TGA TGT TTG TAG GTT TTT GT-3′ (sense) and 5′-AAC TCC ACA CTC TTC CAA AAA CAA AAC A-3′ (antisense) for the unmethylated reaction and 5′-TTT CGA CGT TCG TAG GTT TTC CG-3′ (sense) and 5′ GCA CTC TTC CGA AAA CGA AAC G-3′ (antisense) for the methylated reaction.
The results and conclusions reached in the paper are unaffected by this correction. The primer sequences listed above were correctly given in the manuscript, “Esteller, M., Hamilton, S.R., Burger, P.C., Baylin, S.B., and Herman J.G. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res., 59: 793–797, 1999.”
In the article by W-Y. Zhu et al., entitled “Retinoic acid increases tyrosine phosphorylation of focal adhesion kinase and paxillin in MCF-7 human breast cancer cells,” which appeared in the January 1, 1999 issue of Cancer Research (pp. 85–90), the dosage of RA used in Figures 2 and 5 was incorrectly listed as “1 mM.” The correct dosage of RA used in both of these figures was “1 μM.”